Elicera Therapeutics AB
Research Elicera Therapeutics AB (ELIC) on Bullrun: market cap SEK 168.18M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerELIC
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 168.18M
- Financial periodQ1 2026
- Net income-SEK 5.06M
- Free cash flow-SEK 6.98M
Valuation Snapshot
latest market cap is SEK 168.18M.
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma;
Frequently asked questions
What is Elicera Therapeutics AB's market cap?
Elicera Therapeutics AB's market capitalization is SEK 168.18M.
What does Elicera Therapeutics AB do?
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors;